Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979337275> ?p ?o ?g. }
Showing items 1 to 84 of
84
with 100 items per page.
- W2979337275 abstract "Abstract Abstract 4639 Background. Fludarabine is an effective treatment for chronic lymphocytic leukemia (CLL) alones and in combined terapy in untreatment CLL. The standard recomandation for the stage A Binet, is to delay any treatement until progression. We compared the benefit of early exposure to fludarabine versus no-treatment in the patients with CLL stage A. Methods. Between 2000 and 2004, we randomzed 77 patients with CLL stage A to be treated; fludarabine 25 mg/m2, administered intravenously daily for 5 days every 28 days versus no treatment until disease progression. The treated group with received the assigned treatment for a maximum of 6 cycles. Both groups evaluated evry 2 month diseases progression. The NCI-WG response criteria for CLL was refered for analized result. Results. Among the 38 patients treated by fludarabine. Complet response and parcial response were observed 21 % and 74 % of cases respectively. The median Progression Free Survival (PFS) was 32 month in the treated group versus 31.5 months in the 39 patients of control group, (p 0.9). The median survival were 124 and 122 months respectively, p 0.7. Existing deletion p53, high risk stage A CLL had no impact on the result. The commonest grade III-IV toxicities were neutropenia (12 %) and trombocytopenia (11 %) in the tretaed group. Conclusions. Fludarabine did not prolong PFS and survival in patients with stage A CLL. Despite the low tolerability of fludarabine there is no need to provide an early exposure in patients with stage A CLL. Disclosures: No relevant conflicts of interest to declare." @default.
- W2979337275 created "2019-10-18" @default.
- W2979337275 creator A5004678990 @default.
- W2979337275 creator A5010859244 @default.
- W2979337275 creator A5044903892 @default.
- W2979337275 creator A5046436694 @default.
- W2979337275 creator A5047564001 @default.
- W2979337275 creator A5075171938 @default.
- W2979337275 date "2010-11-19" @default.
- W2979337275 modified "2023-10-01" @default.
- W2979337275 title "Fludarabine Versus No-Treatment In the Patients with CLL Stage A" @default.
- W2979337275 doi "https://doi.org/10.1182/blood.v116.21.4639.4639" @default.
- W2979337275 hasPublicationYear "2010" @default.
- W2979337275 type Work @default.
- W2979337275 sameAs 2979337275 @default.
- W2979337275 citedByCount "0" @default.
- W2979337275 crossrefType "journal-article" @default.
- W2979337275 hasAuthorship W2979337275A5004678990 @default.
- W2979337275 hasAuthorship W2979337275A5010859244 @default.
- W2979337275 hasAuthorship W2979337275A5044903892 @default.
- W2979337275 hasAuthorship W2979337275A5046436694 @default.
- W2979337275 hasAuthorship W2979337275A5047564001 @default.
- W2979337275 hasAuthorship W2979337275A5075171938 @default.
- W2979337275 hasConcept C126322002 @default.
- W2979337275 hasConcept C141071460 @default.
- W2979337275 hasConcept C143998085 @default.
- W2979337275 hasConcept C146357865 @default.
- W2979337275 hasConcept C151730666 @default.
- W2979337275 hasConcept C197934379 @default.
- W2979337275 hasConcept C2776694085 @default.
- W2979337275 hasConcept C2776755627 @default.
- W2979337275 hasConcept C2777063308 @default.
- W2979337275 hasConcept C2777938653 @default.
- W2979337275 hasConcept C2778375690 @default.
- W2979337275 hasConcept C2778461978 @default.
- W2979337275 hasConcept C2779263901 @default.
- W2979337275 hasConcept C2780739268 @default.
- W2979337275 hasConcept C71924100 @default.
- W2979337275 hasConcept C86803240 @default.
- W2979337275 hasConcept C90924648 @default.
- W2979337275 hasConceptScore W2979337275C126322002 @default.
- W2979337275 hasConceptScore W2979337275C141071460 @default.
- W2979337275 hasConceptScore W2979337275C143998085 @default.
- W2979337275 hasConceptScore W2979337275C146357865 @default.
- W2979337275 hasConceptScore W2979337275C151730666 @default.
- W2979337275 hasConceptScore W2979337275C197934379 @default.
- W2979337275 hasConceptScore W2979337275C2776694085 @default.
- W2979337275 hasConceptScore W2979337275C2776755627 @default.
- W2979337275 hasConceptScore W2979337275C2777063308 @default.
- W2979337275 hasConceptScore W2979337275C2777938653 @default.
- W2979337275 hasConceptScore W2979337275C2778375690 @default.
- W2979337275 hasConceptScore W2979337275C2778461978 @default.
- W2979337275 hasConceptScore W2979337275C2779263901 @default.
- W2979337275 hasConceptScore W2979337275C2780739268 @default.
- W2979337275 hasConceptScore W2979337275C71924100 @default.
- W2979337275 hasConceptScore W2979337275C86803240 @default.
- W2979337275 hasConceptScore W2979337275C90924648 @default.
- W2979337275 hasLocation W29793372751 @default.
- W2979337275 hasOpenAccess W2979337275 @default.
- W2979337275 hasPrimaryLocation W29793372751 @default.
- W2979337275 hasRelatedWork W1990815726 @default.
- W2979337275 hasRelatedWork W2085074066 @default.
- W2979337275 hasRelatedWork W2092542029 @default.
- W2979337275 hasRelatedWork W2142604819 @default.
- W2979337275 hasRelatedWork W2245336055 @default.
- W2979337275 hasRelatedWork W2255109913 @default.
- W2979337275 hasRelatedWork W2260296716 @default.
- W2979337275 hasRelatedWork W2351803983 @default.
- W2979337275 hasRelatedWork W2462429923 @default.
- W2979337275 hasRelatedWork W2485364093 @default.
- W2979337275 hasRelatedWork W2523669856 @default.
- W2979337275 hasRelatedWork W2550265197 @default.
- W2979337275 hasRelatedWork W2551822051 @default.
- W2979337275 hasRelatedWork W2571254774 @default.
- W2979337275 hasRelatedWork W2586736954 @default.
- W2979337275 hasRelatedWork W2901646610 @default.
- W2979337275 hasRelatedWork W2979663997 @default.
- W2979337275 hasRelatedWork W3109434564 @default.
- W2979337275 hasRelatedWork W3131584132 @default.
- W2979337275 hasRelatedWork W1745646308 @default.
- W2979337275 isParatext "false" @default.
- W2979337275 isRetracted "false" @default.
- W2979337275 magId "2979337275" @default.
- W2979337275 workType "article" @default.